United Kingdom · Question · Written question
HL HL3236
Amivantamab
Introduced
5 December 2024
Last action
12 December 2024 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
12 December 2024
Summary
To ask His Majesty's Government what discussions they have had with the National Institute for Health and Care Excellence regarding the licensing of Amivantamab for the treatment of NHS cancer patients; and when they expect a licence to be granted.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
5 December 2024
Written question
To ask His Majesty's Government what discussions they have had with the National Institute for Health and Care Excellence regarding the licensing of Amivantamab for the treatment of NHS cancer patients; and when they expect a licence to be granted.
Source: Lords
12 December 2024
Answer
Department officials have regular discussions with colleagues in the National Institute for Health and Care Excellence (NICE) about a range of issues, including access to new treatments for a range of diseases and conditions.Amivantamab was granted a cond...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2024-12-05/HL3236
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1747546
- uk · wq-1747546 · source updated 12 December 2024